Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma: a meta-analysis

References

• Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004;23:6524–6534.
   PubMed Web of Science ®Google Scholar
• Sehn LH. Early detection of patients with poor risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2009;50:1744–1747.
   PubMed Web of Science ®Google Scholar
• Kanemasa Y, Shimoyama T, Sasaki Y. Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients. Med Oncol. 2017;34:29.
   PubMed Web of Science ®Google Scholar
• He X, Chen Z, Fu T, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;14:153.
   PubMed Web of Science ®Google Scholar
• Woo HD, Kim K, Kim J. Association between preoperative C-reactive protein level and colorectal cancer survival: a meta-analysis. Cancer Causes Control. 2015;26:1661–1670.
   PubMed Web of Science ®Google Scholar
• Luo Y, Fu SJ, She DL, et al. Preoperative C-reactive protein as a prognostic predictor for upper tract urothelial carcinoma: a systematic review and meta-analysis. Mol Clin Oncol. 2015;3:924–928.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou M, Wang X, et al. Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP. Clin Chim Acta. 2016;459:150–154.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Chung JS, Song MK, et al. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2012;69:1165–1172.
   PubMed Web of Science ®Google Scholar
• Melchardt T, Troppan K, Weiss L, et al. Independent prognostic value of serum markers in diffuse large B-cell lymphoma in the era of the NCCN-IPI. J Natl Compr Canc Netw. 2015;13:1501–1508.
   PubMed Web of Science ®Google Scholar
• Miyashita K, Tomita N, Taguri M, et al. Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy. Leukemia Res. 2015;39:1187–1191.
   Google Scholar
• Tadmor T, Fell R, Polliack A, et al. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol. 2013; 31:65–71.
   PubMed Web of Science ®Google Scholar
• Xingying L. A study on the clinical characteristics and prognostic factors of diffuse large B–cell Lymphoma. Diss. Hebei Medical University; 2011.
   Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle–Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25:603–605.
   PubMed Web of Science ®Google Scholar
• Yonetani N, Kurata M, Nishikori M, et al. Primary mediastinal large B-cell lymphoma: a comparative study with nodular sclerosis-type Hodgkin's disease. Int J Hematol. 2001;74:178–185.
   PubMed Web of Science ®Google Scholar
• Todorovic M, Balint B, Andjelic B, et al. Switching to BCL-6 negativity in relapsed diffuse large B cell lymphoma correlated with more aggressive disease course. Indian J Hematol Blood Transfus. 2014;30:269–274.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Nakamine H, Okamoto M, et al. Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10:2482–2490.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Zhao W, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol. 2015;94:57–63.
   PubMed Web of Science ®Google Scholar
• Hong JY, Ryu KJ, Lee JY, et al. Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma. Hematol Oncol. 2017;35:480–486.
   PubMedGoogle Scholar
• Brunet V, Marouan S, Routy JP, et al. Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: a retrospective study of 29 case reports. Medicine (Baltimore). 2017;96:e5985.
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Polizzotto MN, Wyvill K, et al. Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas are associated with markedly elevated serum IL-10, elevated IL-6, IL-17 and circulating KSHV. Infect Agents Cancer. 2012;7:P39.
   Google Scholar
• Iioka F, Izumi K, Kamoda Y, et al. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy. Int J Clin Oncol. 2016;21:498–505.
   PubMed Web of Science ®Google Scholar
• Conroy SM, Maskarinec G, Morimoto Y, et al. Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case–control study: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2013;22:337–347.
   Google Scholar
• Pavlů J, Auner HW, Ellis S, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematol Oncol. 2011;29:75–80.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim YR, Kim SJ, et al. The role of modified Glasgow Prognostic Score as predictor in diffuse large B cell lymphoma treated with the R-CHOP regimen. Blood. 2013;122:4389.
   Google Scholar
• Kim Y, Kim SJ, Hwang D, et al. The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen. Yonsei Med J. 2014;55:1568–1575.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Terui Y, Mishima Y, et al. Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory malignant lymphoma. Blood. 2011;118:3659.
   PubMedGoogle Scholar
• Suzuki K, Terui Y, Nishimura N, et al. Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma. Jpn J Clin Oncol. 2013;43:37–44.
   PubMed Web of Science ®Google Scholar
• Adams HJ, de Klerk JM, Fijnheer R, et al. Prognostic value of anemia and C-reactive protein levels in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15:671–679.
   PubMed Web of Science ®Google Scholar
• Cao Y, Shi YX, Chen JO, et al. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumor Biol. 2012; 33:1039–1044.
   PubMed Web of Science ®Google Scholar
• Troppan KT, Schlick K, Deutsch A, et al. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer. 2014;111:55–60.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kuroda J, Yokota I, et al. The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era. Blood. 2016;6:e383.
   Web of Science ®Google Scholar
• Jung SH, Yang DH, Ahn JS, et al. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma. Acta Haematol. 2015;133:10–17.
   PubMed Web of Science ®Google Scholar
• Huang Q, Wang Z, Li Y, et al. Prognostic significance of serum C-reactive protein in diffuse large B-cell lymphoma. Cancer Res Clin. 2016;28:244–247.
   Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455.
   PubMed Web of Science ®Google Scholar
• Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117:104–111.
   PubMed Web of Science ®Google Scholar
• Hoffmann JA, Kafatos FC, Janeway CA, et al. Phylogenetic perspectives in innate immunity. Science. 1999;284:1313–1318.
   PubMed Web of Science ®Google Scholar
• Huang Y, Feng J, Liu J, et al. Prognostic role of serum C-reactive protein in esophageal cancer: a systematic review and meta-analysis. Ther Clin Risk Manag. 2015;11:89–94.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. J Clin Immunol. 2008;454:436–444.
   Google Scholar
• Kaplan M, Volanakis J. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol. 1974; 112:2135–2147.
   PubMed Web of Science ®Google Scholar
• Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48:155–170.
   PubMed Web of Science ®Google Scholar
• Li N, Tian GW, Wang Y, et al. Prognostic role of the pretreatment C-reactive protein/albumin ratio in solid cancers: a meta-analysis. Sci Rep. 2017;7:41298.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou X, Liu Y, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: a meta-analysis. PLoS One. 2017; 12:e0176008.
   PubMed Web of Science ®Google Scholar
• Feng J, Wang Z, Guo X, et al. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. Int J Hematol. 2012;95:143–148.
   PubMed Web of Science ®Google Scholar
• Lin B, Chen C, Qian Y, et al. Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis. Leuk Lymphoma. 2015;56:2563–2568.
   PubMed Web of Science ®Google Scholar